SRC and Miyoshi myopathy: Supporting this hypothesis, treatment with the src inhibitor dasatinib augmented sensitivity to CHK1 inhibition (with UCN-01) in MM cell lines, primary CD138+ cells from MM patients, and mouse xenograft mouse models (86).